



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



SR 4835

Item No. 39158

CAS Registry No.: 2387704-62-1
Formal Name: N-[(5,6-dichloro-1H-benzimidazol-2-yl)methyl]-9-(1-methyl-1H-pyrazol-4-yl)-2-(4-morpholinyl)-9H-purin-6-amine

MF: C₂₁H₂₀Cl₂N₁₀O
FW: 499.4


Purity: ≥98%

UV/Vis.: λ_{max}: 212, 293, 299 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SR 4835 is supplied as a solid. A stock solution may be made by dissolving the SR 4835 in the solvent of choice, which should be purged with an inert gas. SR 4835 is soluble in DMSO and methanol.

Description

SR 4835 is an inhibitor of cyclin-dependent kinase 12 (Cdk12) and Cdk13.¹ It binds to Cdk12 and Cdk13 (K_ds = 98 and 4.9 nM, respectively) and inhibits Cdk12- and Cdk13-dependent phosphorylation of RNA polymerase II in MDA-MB-231 cells (EC₅₀ = 105.5 nM). SR 4835 inhibits the proliferation of MDA-MB-231, MDA-MB-468, Hs 578T, and MDA-MB-436 breast cancer cells (EC₅₀s = 15.5, 22.1, 19.9, and 24.9 nM, respectively). It induces the DNA damage response and apoptosis in MDA-MB-231 cells when used at concentrations ranging from 30 to 90 nM. *In vivo*, SR 4835 (20 mg/kg) reduces tumor volume and decreases the number of mice with tumors greater than 1,000 mm³ in a patient-derived xenograft (PDX) model of breast cancer.

Reference

1. Quereda, V., Bayle, S., Vena, F., *et al.* Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer. *Cancer Cell* **36**(5), 545-558 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM